Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.

Fabienne Englmeier; Annalen Bleckmann; Wolfgang  Brückl; Frank Griesinger; Annette Fleitz; Klaus Nagels

doi:10.1007/s00432-022-04034-w

Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.

Fabienne Englmeier, Annalen Bleckmann, Wolfgang Brückl (Co-author), Frank Griesinger, Annette Fleitz, Klaus Nagels

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Original Article › peer-review

19 Citations (Web of Science)

Original language	English
Pages (from-to)	1495-1511
Journal	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume	149
Issue number	4
DOIs	https://doi.org/10.1007/s00432-022-04034-w
Publication status	Published - 2023

Keywords

1ST-LINE TREATMENT
OPEN-LABEL
ALK
EGFR
CHEMOTHERAPY
CRIZOTINIB
PEMBROLIZUMAB
EPIDEMIOLOGY
IMPACT

Access to Document

10.1007/s00432-022-04034-w

Cite this

Englmeier, F., Bleckmann, A., Brückl, W., Griesinger, F., Fleitz, A., & Nagels, K. (2023). Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , 149(4), 1495-1511. https://doi.org/10.1007/s00432-022-04034-w

Englmeier, Fabienne ; Bleckmann, Annalen ; Brückl, Wolfgang et al. / Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 2023 ; Vol. 149, No. 4. pp. 1495-1511.

@article{ea1ac8784ca64695ae5f723bdb71f5fb,

title = "Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.",

keywords = "1ST-LINE TREATMENT, OPEN-LABEL, ALK, EGFR, CHEMOTHERAPY, CRIZOTINIB, PEMBROLIZUMAB, EPIDEMIOLOGY, IMPACT",

author = "Fabienne Englmeier and Annalen Bleckmann and Wolfgang Br{\"u}ckl and Frank Griesinger and Annette Fleitz and Klaus Nagels",

note = "Br{\"u}ckl: Department of Respiratory Medicine, Allergology and Sleep Medicine, Nuremberg Lung Cancer Center, General Hospital Nuremberg, Paracelsus Medical University, Prof.-Ernst-Nathan-Stra{\ss}e 1, 90419, Nuremberg, Germany",

year = "2023",

doi = "10.1007/s00432-022-04034-w",

language = "English",

volume = "149",

pages = "1495--1511",

journal = "JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY ",

issn = "0171-5216",

publisher = "Springer Nature",

number = "4",

}

Englmeier, F, Bleckmann, A, Brückl, W, Griesinger, F, Fleitz, A & Nagels, K 2023, 'Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.', JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol. 149, no. 4, pp. 1495-1511. https://doi.org/10.1007/s00432-022-04034-w

Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. / Englmeier, Fabienne; Bleckmann, Annalen; Brückl, Wolfgang (Co-author) et al.
In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , Vol. 149, No. 4, 2023, p. 1495-1511.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.

AU - Englmeier, Fabienne

AU - Bleckmann, Annalen

AU - Brückl, Wolfgang

AU - Griesinger, Frank

AU - Fleitz, Annette

AU - Nagels, Klaus

N1 - Brückl: Department of Respiratory Medicine, Allergology and Sleep Medicine, Nuremberg Lung Cancer Center, General Hospital Nuremberg, Paracelsus Medical University, Prof.-Ernst-Nathan-Straße 1, 90419, Nuremberg, Germany

PY - 2023

Y1 - 2023

KW - 1ST-LINE TREATMENT

KW - OPEN-LABEL

KW - ALK

KW - EGFR

KW - CHEMOTHERAPY

KW - CRIZOTINIB

KW - PEMBROLIZUMAB

KW - EPIDEMIOLOGY

KW - IMPACT

U2 - 10.1007/s00432-022-04034-w

DO - 10.1007/s00432-022-04034-w

M3 - Original Article

C2 - 35532791

SN - 0171-5216

VL - 149

SP - 1495

EP - 1511

JO - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

JF - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

IS - 4

ER -

Englmeier F, Bleckmann A, Brückl W, Griesinger F, Fleitz A, Nagels K. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY . 2023;149(4):1495-1511. doi: 10.1007/s00432-022-04034-w